Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0SGXZO
ADC Name
huHEA125-amanitin4
Synonyms
huHEA125 Amanitin4
   Click to Show/Hide
Organization
Heidelberg Pharma AG
Drug Status
Investigative
Indication
In total 4 Indication(s)
Breast cancer
Investigative
.
Cholangiocarcinoma
Investigative
.
Colon adenocarcinoma
Investigative
.
Pancreatic ductal adenocarcinoma
Investigative
.
Drug-to-Antibody Ratio
3
Antibody Name
huHEA125
  Antibody Info 
Antigen Name
Epithelial cell adhesion molecule (EPCAM)
  Antigen Info 
Payload Name
Beta-amanitin
  Payload Info 
Therapeutic Target
DNA-directed RNA polymerase II subunit RPB2 (POLR2B); DNA-directed RNA polymerase III subunit RPC7 (POLR3G)
  Target Info 
Linker Name
huHEA125-Amanitin4 linker
Conjugate Type
Random conjugation through nucleophilic lysines.
General Information of The Activity Data Related to This ADC
Revealed Based on the Cell Line Data
Click To Hide/Show 1 Activity Data Related to This Level
Standard Type Value Units Cell Line Disease Model
Half Maximal Inhibitory Concentration (IC50) 
5
pM
CVCL_0031
Invasive breast carcinoma
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
Click To Hide/Show 1 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) 5.00 pM Positive EPCAM expression (EPCAM+++/++)
Method Description
Cells were added in 50 ul at a density of 50,000 per ml in the experiments with ADCs and at a density of 20,000 per ml in the experiments with huHEA125-Amanitin3. Plates were incubated in a humidified atmosphere at 37°C and 5% CO2 for 72 or 96 h. At 20 h before the end of the assay, 1 uCi of H-thymidine was added.
In Vitro Model Invasive breast carcinoma MCF-7 cells CVCL_0031
References
Ref 1 Amatoxin-armed therapeutic cell surface binding components designed for tumour therapy.